Related references
Note: Only part of the references are listed.CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
Meredith M. Regan et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
CYP2D6 Inhibition and Breast Cancer Recurrence in a Population-Based Study in Denmark
Timothy L. Lash et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes
Deirdre P Cronin-Fenton et al.
Expert Review of Clinical Pharmacology (2011)
Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis
Bostjan Seruga et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole
Landry K. Kamdem et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Evidence and Practice Regarding the Role for CYP2D6 Inhibition in Decisions About Tamoxifen Therapy
Timothy L. Lash et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
Jack Cuzick et al.
LANCET ONCOLOGY (2010)
Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
Werner Schroth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Richard M. Simon et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Genotype-guided tamoxifen therapy: time to pause for reflection?
Timothy L. Lash et al.
LANCET ONCOLOGY (2009)
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients
J. M. Rae et al.
PHARMACOGENOMICS JOURNAL (2009)
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
Bryan P. Schneider et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer:: A modeling analysis
Rinaa S. Punglia et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?
Daniel F. Hayes et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial
Jack Cuzick et al.
LANCET ONCOLOGY (2008)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
Norman Williams
LANCET ONCOLOGY (2008)
The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype
A. Gaedigk et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Tamoxifen pharmacogenomics: The role of CYP2D6 as a predictor of drug response
M. P. Goetz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes
Werner Schroth et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases
Dongxiao Sun et al.
DRUG METABOLISM AND DISPOSITION (2007)
Concordance of pharmacogenetic polymorphisms in tumor and germ line DNA in adult patients with acute myeloid leukemia
Joli R. Weiss et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2007)
Ontogeny of dextromethorphan O- and N-demethylation in the first year of life
M. J. Blake et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
Pia Wegman et al.
BREAST CANCER RESEARCH (2007)
Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells
Young Chai Lim et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial
A. Buzdar et al.
LANCET ONCOLOGY (2006)
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism:: Implication for optimization of breast cancer treatment
Silvana Borges et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes
MP Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
Y Jin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
A Howell et al.
LANCET (2005)
Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen
MD Johnson et al.
BREAST CANCER RESEARCH AND TREATMENT (2004)
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6
Z Desta et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial
L Fallowfield et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
V Stearns et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer - Results of the ATAC (arimidex, tamoxifen alone or in comhination) trial efficacy and safety update analyses
CANCER (2003)
Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen
M Dowsett et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2003)
CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants
LD Bradford
PHARMACOGENOMICS (2002)
Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance
CR Bhasker et al.
PHARMACOGENETICS (2000)
Share Paper
